Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients
The fifteen-month dataset represents the final analysis from the Phase 1/2 study At the Month 15 primary timepoint,…